Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
editorial
. 1991 Sep 14;303(6803):594–595. doi: 10.1136/bmj.303.6803.594

More macrolides.

M J Wood
PMCID: PMC1671102  PMID: 1932896

Full text

PDF
594

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson G., Esmonde T. S., Coles S., Macklin J., Carnegie C. A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia. J Antimicrob Chemother. 1991 Feb;27 (Suppl A):117–124. doi: 10.1093/jac/27.suppl_a.117. [DOI] [PubMed] [Google Scholar]
  2. Chantot J. F., Bryskier A., Gasc J. C. Antibacterial activity of roxithromycin: a laboratory evaluation. J Antibiot (Tokyo) 1986 May;39(5):660–668. doi: 10.7164/antibiotics.39.660. [DOI] [PubMed] [Google Scholar]
  3. Davies B. I., Maesen F. P., Gubbelmans R. Azithromycin (CP-62,993) in acute exacerbations of chronic bronchitis: an open clinical, microbiological and pharmacokinetic study. J Antimicrob Chemother. 1989 May;23(5):743–751. doi: 10.1093/jac/23.5.743. [DOI] [PubMed] [Google Scholar]
  4. Fernandes P. B., Ramer N., Rode R. A., Freiberg L. Bioassay for A-56268 (TE-031) and identification of its major metabolite, 14-hydroxy-6-O-methyl erythromycin. Eur J Clin Microbiol Infect Dis. 1988 Feb;7(1):73–76. doi: 10.1007/BF01962181. [DOI] [PubMed] [Google Scholar]
  5. Fitzgeorge R. B., Featherstone A. S., Baskerville A. Efficacy of azithromycin in the treatment of guinea pigs infected with Legionella pneumophila by aerosol. J Antimicrob Chemother. 1990 Jan;25 (Suppl A):101–108. doi: 10.1093/jac/25.suppl_a.101. [DOI] [PubMed] [Google Scholar]
  6. Foulds G., Shepard R. M., Johnson R. B. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother. 1990 Jan;25 (Suppl A):73–82. doi: 10.1093/jac/25.suppl_a.73. [DOI] [PubMed] [Google Scholar]
  7. Girard A. E., Girard D., Retsema J. A. Correlation of the extravascular pharmacokinetics of azithromycin with in-vivo efficacy in models of localized infection. J Antimicrob Chemother. 1990 Jan;25 (Suppl A):61–71. doi: 10.1093/jac/25.suppl_a.61. [DOI] [PubMed] [Google Scholar]
  8. Grayston J. T., Kuo C. C., Wang S. P., Altman J. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med. 1986 Jul 17;315(3):161–168. doi: 10.1056/NEJM198607173150305. [DOI] [PubMed] [Google Scholar]
  9. Hardy D. J., Hensey D. M., Beyer J. M., Vojtko C., McDonald E. J., Fernandes P. B. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob Agents Chemother. 1988 Nov;32(11):1710–1719. doi: 10.1128/aac.32.11.1710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hardy D. J., Swanson R. N., Rode R. A., Marsh K., Shipkowitz N. L., Clement J. J. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob Agents Chemother. 1990 Jul;34(7):1407–1413. doi: 10.1128/aac.34.7.1407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Karma P., Pukander J., Penttilä M., Ylikoski J., Savolainen S., Olén L., Melén I., Löth S. The comparative efficacy and safety of clarithromycin and amoxycillin in the treatment of outpatients with acute maxillary sinusitis. J Antimicrob Chemother. 1991 Feb;27 (Suppl A):83–90. doi: 10.1093/jac/27.suppl_a.83. [DOI] [PubMed] [Google Scholar]
  12. Olsson-Liljequist B., Hoffman B. M. In-vitro activity of clarithromycin combined with its 14-hydroxy metabolite A-62671 against Haemophilus influenzae. J Antimicrob Chemother. 1991 Feb;27 (Suppl A):11–17. doi: 10.1093/jac/27.suppl_a.11. [DOI] [PubMed] [Google Scholar]
  13. Poirier R. Comparative study of clarithromycin and roxithromycin in the treatment of community-acquired pneumonia. J Antimicrob Chemother. 1991 Feb;27 (Suppl A):109–116. doi: 10.1093/jac/27.suppl_a.109. [DOI] [PubMed] [Google Scholar]
  14. Powell M. Chemotherapy for infections caused by Haemophilus influenzae: current problems and future prospects. J Antimicrob Chemother. 1991 Jan;27(1):3–7. doi: 10.1093/jac/27.1.3. [DOI] [PubMed] [Google Scholar]
  15. Pullar T., Birtwell A. J., Wiles P. G., Hay A., Feely M. P. Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily. Clin Pharmacol Ther. 1988 Nov;44(5):540–545. doi: 10.1038/clpt.1988.191. [DOI] [PubMed] [Google Scholar]
  16. Steingrimsson O., Olafsson J. H., Thorarinsson H., Ryan R. W., Johnson R. B., Tilton R. C. Azithromycin in the treatment of sexually transmitted disease. J Antimicrob Chemother. 1990 Jan;25 (Suppl A):109–114. doi: 10.1093/jac/25.suppl_a.109. [DOI] [PubMed] [Google Scholar]
  17. Washington J. A., 2nd, Wilson W. R. Erythromycin: a microbial and clinical perspective after 30 years of clinical use (2). Mayo Clin Proc. 1985 Apr;60(4):271–278. doi: 10.1016/s0025-6196(12)60322-x. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES